Tarsus Pharmaceuticals, Inc. (TARS) Stock Price & Analysis
Tarsus Pharmaceuticals, Inc. (TARS) rose 3.20% to USD 61.55 as of June 10, 2026 at 02:22 UTC, according to Nexqual real-time market data.
TARS last closed at USD 59.64; the session ranged USD 60.26–62.64 on volume of 615,559 shares. Market capitalization is $2.65B, with a 52-week range of USD 38.51–85.25 (NMS). Source: Nexqual, June 10, 2026 at 02:22 UTC.
Key Statistics (as of June 10, 2026 at 02:22 UTC)
| Price | USD 61.55 |
|---|---|
| Change | ▲ 3.20% (up) |
| Previous Close | USD 59.64 |
| Open | USD 60.26 |
| Day Range | USD 60.26 – 62.64 |
| 52-Week Range | USD 38.51 – 85.25 |
| Volume | 615,559 shares |
| Market Cap | $2.65B |
| Exchange | NMS |
Technical Analysis (TARS)
Nexqual's technical model rates TARS "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 02:22 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.91 (neutral) |
| vs SMA50 | Below (USD 64.32) |
| MACD | -1.21 (negative) |
Analyst Ratings (TARS)
Wall Street analysts rate TARS "Strong Buy" based on 9 analysts, with a mean price target of USD 94.11 (range USD 88–100), per Nexqual as of June 10, 2026 at 02:22 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 94.11 |
| High Target | USD 100 |
| Low Target | USD 88 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (TARS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.25 |
| Revenue Estimate | $167.36M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.16 vs est -0.42 ▲ beat |
| 2025-12-31 | USD -0.2 vs est 0.01 ▼ miss |
| 2025-09-30 | USD -0.3 vs est -0.33 ▲ beat |
| 2025-06-30 | USD -0.48 vs est -0.36 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Financials & Fundamentals (TARS)
| Total Revenue | $535.08M |
|---|---|
| Revenue Growth (YoY) | +106.90% |
| Gross Margin | +79.98% |
| Operating Margin | -3.78% |
| Profit Margin | -9.02% |
| ROE | -13.96% |
| Debt / Equity | 25.41 |
| Current Ratio | 3.74 |
| Total Cash | $388.73M |
| Total Debt | $88.68M |
| Free Cash Flow | $-21.27M |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Financial Health Score (TARS)
Nexqual rates Tarsus Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:22 UTC.
| Growth | Strong — Revenue +147% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 80%, operating -4% |
| Balance Sheet | Strong — $389M cash vs $89M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$21M, burning cash |
| Efficiency | Critical — ROE -14%, ROA -5.9% |
Ownership (TARS)
| Insider Ownership | +3.07% |
|---|---|
| Institutional Ownership | +109.76% |
| Shares Outstanding | 43.02M |
| Float | 32.12M |
| Short % of Float | +12.31% |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Leadership (TARS)
Tarsus Pharmaceuticals, Inc. is led by Bobak R. Azamian, Co-Founder, President, CEO & Chairman, per Nexqual as of June 10, 2026 at 02:22 UTC.
| Co-Founder, President, CEO & Chairman | Bobak R. Azamian |
|---|---|
| CFO & Chief Strategy Officer | Jeffrey S. Farrow (age 63) |
| Chief Operating Officer | Seshadri Neervannan (age 57) |
| Senior Director of Corporate Communications | Adrienne Kemp |
| Vice President of Marketing | Matthew Rossen (age 47) |
Major Backers & Investors (TARS)
Notable institutional backers of Tarsus Pharmaceuticals, Inc. include Deep Track Capital, Lp, RTW Investments LP, Paradigm Biocapital Advisors LP, according to Nexqual as of June 10, 2026 at 02:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 8.37% |
| RTW Investments LP | 7.78% |
| Paradigm Biocapital Advisors LP | 5.96% |
| Janus Henderson Group PLC | 5.21% |
| Morgan Stanley | 4.52% |
| Jennison Associates LLC | 3.98% |
| Assenagon Asset Management S.A. | 2.98% |
| Bank of America Corporation | 2.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.86% |
| Vanguard Group | 8.08% |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
From Tarsus Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Approach: TP-04 Topical Formulation for Ocular Rosacea There are no FDA-approved therapeutics for ocular rosacea available today.
- Intellectual Property We protect our intellectual property rights and proprietary technology with a combination of patent rights that we own or license in certain fields of use, trademark rights, confidentiality procedures and contractual provisions.
- We seek not only to protect our intellectual property rights and proprietary technology in select key global markets, but also to supplement our intellectual property portfolio with new filings and applications to enhance such protection and support commercialization of current and future product candidates.
- Our continuing research and development activities, technical expertise and contractual arrangements supplement our existing intellectual property protection and help us maintain our competitive position, and we rely on trade secrets to protect our proprietary information and technologies, especially where we do not believe patent protection is appropriate or obtainable, or where such patents would be difficult to enforce.
Partnerships
- In March 2024, we executed an agreement with GrandPharma and LianBio to transition these rights to GrandPharma.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | USD 9.82 | ▼ 3.06% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 9.23 | ▲ 6.83% |
| PRAX | Praxis Precision Medicines, Inc | USD 250.33 | ▼ 1.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:22 UTC. This page is informational and not investment advice.